Wegovy: Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks and strokes by 20%

In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss but has also shown a remarkable reduction in the risk of heart disease.

Related Keywords

United States ,United Kingdom ,Denmark ,Canada ,Danish ,Wegovymartin Holst Lange ,Novo Nordisk ,Martin Holst Lange ,Soren Lontoft Hansen ,Barclays ,Eli Lilly Co ,Development At Novo Nordisk ,Daily International News Updates ,International Breaking News Events ,Holst Lange ,Executive Vice President ,Eli Lilly ,Emily Field ,Economic Times ,United Kingdom News ,Canada News ,Latest News Updates ,Economic Times News App ,Daily International News ,Wegovy ,Obesity Drug ,Heart Attacks ,Stroke ,Resonance ,